MINI REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1636483
This article is part of the Research TopicExploring immune low-response states through single-cell technologies and spatial transcriptomicsView all 9 articles
Single-Cell Technologies and Spatial Transcriptomics: Decoding Immune Low -Response States in Endometrial Cancer
Provisionally accepted
- 1Shandong University of Traditional Chinese Medicine, Jinan, China
- 2Jinan municipal Hospital of Traditional Chinese Medicine, Jinan, China
- 3Shandong Provincial Hospital affiliated with Shandong First Medical University, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Globally, endometrial cancer continues to impact a significant number of women. Immunotherapy provides those suffering from advanced or relapsed disease hope, but an important barrier is still the absence of trustworthy predictive biomarkers. To tackle this challenge, single-cell sequencing and spatial transcriptomics (ST) are increasingly applied. In cervical cancers of the no specific molecular profile (NSMP) subtype accompanied by p53 mutations. In many cases, the tumor microenvironment (TME) in endometrial cancer exhibits strong immunosuppression or poor immune cell infiltration, often leading to worse clinical outcomes. Single-cell sequencing reveals cellular heterogeneity and helps identify potential therapeutic targets and predict treatment responses. Conversely, ST assists in determining biomarkers that influence the effectiveness of immunotherapy by capturing the spatial organization of tumors. When combined, these technologies allow for integrated multi-omics analysis that aids in the development of immunotherapies, prognostication, and diagnosis. But there are still moral and legal issues. Clinicians may be able to improve outcomes for patients who don't respond well to current immunotherapies by utilizing these combined approaches.
Keywords: single-cell sequencing, Spatial transcriptomics, Tumor microenvironment (TME), Immunotherapy, endometrial cancer
Received: 28 May 2025; Accepted: 16 Jun 2025.
Copyright: © 2025 Li, Qiu, Zhao, Qi and Cai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yumeng Li, Shandong University of Traditional Chinese Medicine, Jinan, China
Pingping Cai, Shandong Provincial Hospital affiliated with Shandong First Medical University, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.